Zelandopam hydrochloride
Zelandopam hydrochloride has been in phase II clinical trials for the treatment of heart failure and hypertension. However, no recent development has been reported.
The compound was originally developed by Yamanouchi (now Astellas), and then licensed to Mochida.
General Information
Update Date：2016-01-26
- Drug Name：
- Zelandopam hydrochloride
- Research Code：
- MYD-37; YM-435
- Trade Name：
- MOA：
- Dopamine D1 agonist
- Indication：
- Heart failure; Hypertension
- Status：
- Phase II (Pending)
- Company：
- Astellas (Originator) , Mochida
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-26
|
Molecular Weight | 327.76 | ||||||||||||
| Formula | C15H15NO4 • HCl • H2O | |||||||||||||
| CAS No. | 139233-53-7 (Zelandopam (Free)); | |||||||||||||
| Chemical Name | ||||||||||||||
| Zelandopam (Free) （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||